{
  "transcript_summary": "Johnson & Johnson reported Q1 2025 results with 4.2% operational sales growth, raised its full-year operational revenue guidance following the IntraCellular acquisition, and addressed the impact of new tariffs on its MedTech business.",
  "claims": [
    {
      "speaker_role": "management",
      "scale": "billions",
      "metric_context": "Total",
      "gaap_classification": "gaap",
      "claimed_value": 21.9,
      "claimed_value_raw": "$21.9 billion",
      "is_approximate": false,
      "speaker": "Jessica Moore",
      "quote_text": "worldwide sales were $21.9 billion for the quarter.",
      "claim_id": "claim_001",
      "claim_type": "absolute",
      "quote_start_char": 14211,
      "metric_type": "revenue",
      "quote_end_char": 14262,
      "period": "Q1 2025",
      "confidence": 1,
      "unit": "dollars"
    },
    {
      "claim_id": "claim_002",
      "claim_type": "yoy_growth",
      "metric_type": "revenue",
      "quote_start_char": 2749,
      "qualifiers": [
        "operational"
      ],
      "confidence": 1,
      "unit": "percent",
      "period": "Q1 2025",
      "quote_end_char": 2844,
      "scale": "ones",
      "speaker_role": "ceo",
      "comparison_period": "Q1 2024",
      "gaap_classification": "non_gaap",
      "metric_context": "Total",
      "claimed_value": 4.2,
      "is_approximate": false,
      "claimed_value_raw": "4.2%",
      "speaker": "Joaquin Duato",
      "quote_text": "In the first quarter, we delivered strong operational sales growth of 4.2% across our business."
    },
    {
      "claim_id": "claim_003",
      "claim_type": "absolute",
      "quote_start_char": 14504,
      "metric_type": "net_income",
      "period": "Q1 2025",
      "quote_end_char": 14533,
      "unit": "dollars",
      "confidence": 1,
      "speaker_role": "management",
      "scale": "billions",
      "gaap_classification": "gaap",
      "metric_context": "Total",
      "claimed_value": 11,
      "claimed_value_raw": "$11 billion",
      "is_approximate": false,
      "speaker": "Jessica Moore",
      "quote_text": "net earnings were $11 billion"
    },
    {
      "claimed_value": 4.54,
      "claimed_value_raw": "$4.54",
      "is_approximate": false,
      "speaker": "Jessica Moore",
      "quote_text": "diluted earnings per share was $4.54",
      "speaker_role": "management",
      "scale": "ones",
      "metric_context": "Total",
      "gaap_classification": "gaap",
      "quote_end_char": 14574,
      "period": "Q1 2025",
      "confidence": 1,
      "unit": "per_share",
      "claim_id": "claim_004",
      "claim_type": "absolute",
      "quote_start_char": 14538,
      "metric_type": "eps_diluted"
    },
    {
      "quote_text": "adjusted net earnings for the quarter were $6.7 billion",
      "speaker": "Jessica Moore",
      "claimed_value_raw": "$6.7 billion",
      "is_approximate": false,
      "claimed_value": 6.7,
      "gaap_classification": "non_gaap",
      "metric_context": "Total",
      "speaker_role": "management",
      "scale": "billions",
      "period": "Q1 2025",
      "quote_end_char": 14840,
      "confidence": 1,
      "unit": "dollars",
      "qualifiers": [
        "adjusted"
      ],
      "quote_start_char": 14785,
      "metric_type": "net_income",
      "claim_type": "absolute",
      "claim_id": "claim_005"
    },
    {
      "quote_start_char": 14845,
      "metric_type": "eps_diluted",
      "claim_type": "absolute",
      "claim_id": "claim_006",
      "quote_end_char": 14890,
      "period": "Q1 2025",
      "confidence": 1,
      "unit": "per_share",
      "qualifiers": [
        "adjusted"
      ],
      "metric_context": "Total",
      "gaap_classification": "non_gaap",
      "speaker_role": "management",
      "scale": "ones",
      "quote_text": "adjusted diluted earnings per share was $2.77",
      "speaker": "Jessica Moore",
      "claimed_value_raw": "$2.77",
      "is_approximate": false,
      "claimed_value": 2.77
    },
    {
      "scale": "billions",
      "speaker_role": "management",
      "gaap_classification": "gaap",
      "metric_context": "Innovative Medicine",
      "claimed_value": 13.9,
      "is_approximate": false,
      "claimed_value_raw": "$13.9 billion",
      "speaker": "Jessica Moore",
      "quote_text": "worldwide sales of $13.9 billion increased 4.2%",
      "claim_id": "claim_007",
      "claim_type": "absolute",
      "metric_type": "revenue",
      "quote_start_char": 15222,
      "unit": "dollars",
      "confidence": 1,
      "period": "Q1 2025",
      "quote_end_char": 15269
    },
    {
      "claimed_value": 8,
      "claimed_value_raw": "$8 billion",
      "is_approximate": false,
      "speaker": "Jessica Moore",
      "quote_text": "worldwide sales of $8 billion increased 4.1%",
      "speaker_role": "management",
      "scale": "billions",
      "metric_context": "MedTech",
      "gaap_classification": "gaap",
      "quote_end_char": null,
      "period": "Q1 2025",
      "confidence": 1,
      "unit": "dollars",
      "claim_id": "claim_008",
      "claim_type": "absolute",
      "quote_start_char": null,
      "metric_type": "revenue"
    },
    {
      "gaap_classification": "unknown",
      "metric_context": "Total",
      "speaker_role": "cfo",
      "scale": "billions",
      "quote_text": "We are pleased with free cash flow generation in the quarter of approximately $3.4 billion.",
      "speaker": "Joe Wolk",
      "claimed_value_raw": "$3.4 billion",
      "is_approximate": true,
      "claimed_value": 3.4,
      "quote_start_char": 24826,
      "metric_type": "free_cash_flow",
      "claim_type": "absolute",
      "claim_id": "claim_009",
      "period": "Q1 2025",
      "quote_end_char": 24917,
      "confidence": 1,
      "unit": "dollars",
      "qualifiers": [
        "approximately"
      ]
    },
    {
      "confidence": 1,
      "unit": "dollars",
      "quote_end_char": 26771,
      "period": "FY 2025",
      "qualifiers": [
        "operational"
      ],
      "metric_type": "revenue",
      "quote_start_char": 26629,
      "claim_type": "guidance",
      "claim_id": "claim_010",
      "quote_text": "Therefore, we now expect operational sales growth for the full year to be in the range of 3.3% to 4.3% with a midpoint of $92 billion or 3.8%.",
      "speaker": "Joe Wolk",
      "is_approximate": false,
      "claimed_value_raw": "$92 billion",
      "claimed_value": 92,
      "metric_context": "Total",
      "gaap_classification": "non_gaap",
      "scale": "billions",
      "speaker_role": "cfo"
    },
    {
      "quote_text": "maintain our adjusted reported earnings per share guidance of 6.2% at the midpoint for a range of $10.50 to $10.70",
      "speaker": "Joe Wolk",
      "claimed_value_raw": "$10.60",
      "is_approximate": false,
      "claimed_value": 10.6,
      "metric_context": "Total",
      "gaap_classification": "non_gaap",
      "speaker_role": "cfo",
      "scale": "ones",
      "quote_end_char": 28265,
      "period": "FY 2025",
      "unit": "per_share",
      "confidence": 1,
      "qualifiers": [
        "adjusted reported",
        "midpoint"
      ],
      "quote_start_char": 28151,
      "metric_type": "eps_diluted",
      "claim_type": "guidance",
      "claim_id": "claim_011"
    },
    {
      "qualifiers": [
        "more than"
      ],
      "quote_end_char": 25546,
      "period": "Q1 2025",
      "unit": "dollars",
      "confidence": 1,
      "claim_id": "claim_012",
      "claim_type": "absolute",
      "quote_start_char": 25431,
      "metric_type": "research_and_development",
      "claimed_value": 3,
      "claimed_value_raw": "$3 billion",
      "is_approximate": true,
      "speaker": "Joe Wolk",
      "quote_text": "during the first quarter, we invested more than $3 billion in research and development, approximately 15% of sales.",
      "speaker_role": "cfo",
      "scale": "billions",
      "metric_context": "Total",
      "gaap_classification": "gaap"
    },
    {
      "quote_text": "Innovative medicine margin declined from 42.9% to 42.5%",
      "speaker": "Jessica Moore",
      "is_approximate": false,
      "claimed_value_raw": "42.5%",
      "claimed_value": 42.5,
      "gaap_classification": "non_gaap",
      "metric_context": "Innovative Medicine",
      "scale": "ones",
      "speaker_role": "management",
      "unit": "percent",
      "confidence": 1,
      "quote_end_char": 22465,
      "period": "Q1 2025",
      "qualifiers": [
        "adjusted income before tax"
      ],
      "metric_type": "operating_margin",
      "quote_start_char": 22410,
      "claim_type": "margin",
      "claim_id": "claim_013"
    },
    {
      "speaker": "Jessica Moore",
      "quote_text": "MedTech margin declined from 26.4% to 25.9%",
      "claimed_value": 25.9,
      "claimed_value_raw": "25.9%",
      "is_approximate": false,
      "metric_context": "MedTech",
      "gaap_classification": "non_gaap",
      "speaker_role": "management",
      "scale": "ones",
      "quote_end_char": 22669,
      "period": "Q1 2025",
      "confidence": 1,
      "unit": "percent",
      "qualifiers": [
        "adjusted income before tax"
      ],
      "claim_type": "margin",
      "quote_start_char": 22626,
      "metric_type": "operating_margin",
      "claim_id": "claim_014"
    }
  ],
  "total_claims_found": 14,
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 1,
  "extracted_at": "2026-02-13T11:50:35.677973"
}